Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DC activated CIK + DC
- Development stage
- Unknown
- Lead developer
- Qingdao University
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous
01
Overview
DC activated CIK + DC is a combination cellular immunotherapy regimen consisting of autologous cytokine-induced killer (CIK) cells activated by dendritic cells (DCIK) and a dendritic cell (DC) vaccine. CIK cells are a heterogeneous population of effector cells, primarily CD3+CD56+ NKT cells, that exhibit potent, non-MHC-restricted cytotoxic activity against tumor cells. In this regimen, CIK cells are co-cultured with dendritic cells to enhance their anti-tumor efficacy. The second component is a DC vaccine, where autologous dendritic cells are pulsed with tumor-associated antigens to prime and activate an antigen-specific T-cell immune response. This dual approach aims to combine the rapid, broad-spectrum killing of CIK cells with the durable, specific immunity induced by DC vaccination. It is currently being investigated by Qingdao University in Phase I/II clinical trials for the treatment of malignant glioma.
- Other names
- DCIK combined with DCDC-activated cytokine-induced killer cells combined with dendritic cell treatment
02
Targets
pMHC-II (Peptide-major histocompatibility complex class II complex)MICB (Major histocompatibility complex class i-related protein B)CD28-CD80/CD86 costimulatory pathwayNFKB1 (NF-κB1)
Beyond the preview
Go deeper on DC activated CIK + DC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DC activated CIK + DC.